Regeneron files motion to disqualify firm from patent and antitrust dispute | Motion cites conflict of interest due to ...

4 February 2025 Federal Circuit upholds preliminary injunctions blocking highly similar versions of Eylea | Samsung Biopeis ...

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) received a ‘Hold’ rating from Wells Fargo, which set the company’s stock price ...

Regeneron Inc. seeks to disqualify Kirkland & Ellis from representing its opponent Novartis AG in a major antitrust and ...

Findings that U.S. companies can sue foreign rivals despite limited business operations in the country could dissuade drug ...

Patients with prior treatment for diabetic macular edema (DME) may require more frequent dosing of aflibercept (Eylea), according to a subgroup analysis of the PHOTON trial presented at the recent ...

Regeneron signed a deal with China-based Hansoh Pharma for HS-20094, an investigational, late-stage anti-obesity asset. Per ...

Americares, in partnership with the Healthcare Distribution Alliance, presented its annual Power of Partnership Award to Teva ...

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) is one of the 13 Biotech Stocks with Huge Upside Potential. JPMorgan has ...

Detailed price information for Teva Pharmaceutical Industries ADR (TEVA-N) from The Globe and Mail including charting and ...

Alvotech and Advanz Pharma have inked a deal to expand their commercial partnership to cover three additional biosimilar ...